Progress in monoclonal antibody-based immunotherapy for cancer treatment.
- Author:
Yajun GUO
- Publication Type:Journal Article
- MeSH:
Antibodies, Monoclonal;
therapeutic use;
Antineoplastic Agents;
therapeutic use;
Humans;
Immunization, Passive;
Immunotherapy;
Neoplasms;
therapy
- From:
Chinese Journal of Biotechnology
2015;31(6):857-870
- CountryChina
- Language:Chinese
-
Abstract:
More than 100 years ago, Paul Ehrlich first proposed the "magic bullets" concept in which antibody targeting disease related antigen can fight against human disease. Since then, with the development of hybridoma technology for monoclonal antibody production and cancer serum therapy, immunotherapy based monoclonal antibody bas been used in chinical practice to treat hematological and solid tumor. Up to now, more than 20 recombinant antibody drugs were approved for cancer treatment worldwide. In recent years, the next-generation antibody drug, including immune checkpoint antagonists, bi-specific antibody, and antibody drug conjugates have successfully cured various malignant tumor. This review recalled the history of monoclonal antibody as potent immunotherapy of cancer firstly, and focused on the next-generation antibody drug's mechanism of action, construction strategies, and the side effects in clinic. Lastly, the future trend of anti-tumor antibody drug was also discussed.
